<p>企业金融服务公司在第二季度购买了罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的新头寸，根据该公司在最近向 SEC 提交的文件。该机构投资者购买了 5,108 股公司股票，价值约为 208,000 美元。</p>
<ul>
<li>三只投资超过 1000 亿美元的大型制药股。</li>
</ul>
<p>其他一些机构投资者最近也买卖了 RHHBY 的股票。波士顿共同资产管理公司在第二季度增持了罗氏的股份，增幅为 11.1%。波士顿共同资产管理公司现在拥有 361,833 股公司股票，价值为 14,682,000 美元，此前在上个季度增持了 36,101 股。OLD National Bancorp IN 在第二季度将其在罗氏的持仓提高了 2.9%。OLD National Bancorp IN 现在拥有 261,317 股公司股票，价值为 10,604,000 美元，此前在此期间购买了 7,326 股。Rhumbline Advisers 在第二季度增持了罗氏的股份，增幅为 1.1%。Rhumbline Advisers 现在拥有 108,480 股公司股票，价值为 4,422,000 美元，此前在上个季度增持了 1,228 股。Yousif Capital Management LLC 在第二季度将其在罗氏的持仓增加了 7.8%。Yousif Capital Management LLC 现在拥有 88,547 股公司股票，价值为 3,593,000 美元，此前在此期间增持了 6,395 股。最后，S&amp;CO Inc.在第一季度将其在罗氏的股份提高了 4.1%。S&amp;CO Inc.现在拥有 51,199 股公司股票，价值为 2,101,000 美元，此前在上个季度购买了 2,014 股。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对该公司进行了评论。摩根士丹利在 10 月 29 日的报告中重申了对罗氏股票的 “减持” 评级。汇丰银行在 10 月 2 日的研究报告中将罗氏的评级从 “持有” 上调至 “买入”，并设定了 50.00 美元的目标价。德意志银行在 11 月 11 日的报告中将罗氏的评级从 “卖出” 上调至 “持有”。汇丰全球研究在 10 月 2 日的报告中将罗氏的评级从 “持有” 上调至 “强力买入”。最后，杰富瑞金融集团在 10 月 27 日的研究报告中将罗氏的评级从 “持有” 下调至 “适度卖出”。三位分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “买入”，平均目标价为 50.00 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p><strong>获取我们对 RHHBY 的最新分析</strong></p>
<h2>罗氏股票上涨 2.3%</h2>
<p>RHHBY 股票在周五开盘时为 49.01 美元。罗氏控股公司的一年低点为 34.10 美元，一年高点为 49.20 美元。该股票的 50 日简单移动平均线为 43.38 美元，200 日简单移动平均线为 41.31 美元。</p>
<h2>关于罗氏</h2>
<p>（免费报告）</p>
<ul>
<li>NVIDIA 投资了这两只 AI 股票，你应该投资吗？</li>
</ul>
<p>罗氏控股公司在欧洲、北美、拉丁美洲、亚洲、非洲、澳大利亚和大洋洲从事制药和诊断业务。该公司在贫血、血液和实体肿瘤、皮肤病、血友病、炎症和自身免疫、神经系统疾病、眼科、呼吸系统疾病和移植等治疗领域提供药品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>专家股票交易心理学技巧</li>
<li>MP Materials 股票在财报后飙升——真正原因是什么</li>
<li>股票情绪分析：如何运作</li>
<li>为什么 Palantir 的下滑可能是长期机会的铺垫</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>收入投资者注意：这只 REIT 正在打折</li>
</ul>
<p><strong>想看看其他对 RHHBY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在罗氏吗？</h2>
<p>在考虑罗氏之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而罗氏并不在名单上。</p>
<p>虽然罗氏目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

企业金融服务公司

罗氏(ADR)

<p>企业金融服务公司在第二季度收购了 5,108 股罗氏控股公司，价值 208,000 美元。其他机构投资者也增加了他们的持股。分析师对罗氏的评级不一，有些将其评级上调至 “买入” 或 “强力买入”，而另一些则下调。罗氏的股票开盘价为 49.01 美元，接近其一年高点。该公司在全球范围内从事制药和诊断业务</p>

<p>Enterprise Financial Services Corp purchased a new position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,108 shares of the company's stock, valued at approximately $208,000.</p>
<div class="lb-trans"><p>企业金融服务公司在第二季度购买了罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的新头寸，根据该公司在最近向 SEC 提交的文件。该机构投资者购买了 5,108 股公司股票，价值约为 208,000 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只投资超过 1000 亿美元的大型制药股。</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of RHHBY. Boston Common Asset Management LLC boosted its holdings in shares of Roche by 11.1% in the 2nd quarter. Boston Common Asset Management LLC now owns 361,833 shares of the company's stock valued at $14,682,000 after acquiring an additional 36,101 shares during the last quarter. OLD National Bancorp IN lifted its position in Roche by 2.9% during the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company's stock valued at $10,604,000 after purchasing an additional 7,326 shares during the period. Rhumbline Advisers boosted its holdings in Roche by 1.1% in the second quarter. Rhumbline Advisers now owns 108,480 shares of the company's stock valued at $4,422,000 after purchasing an additional 1,228 shares during the last quarter. Yousif Capital Management LLC grew its position in Roche by 7.8% during the 2nd quarter. Yousif Capital Management LLC now owns 88,547 shares of the company's stock worth $3,593,000 after purchasing an additional 6,395 shares during the period. Finally, S&amp;CO Inc. raised its stake in shares of Roche by 4.1% during the 1st quarter. S&amp;CO Inc. now owns 51,199 shares of the company's stock valued at $2,101,000 after buying an additional 2,014 shares during the last quarter.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了 RHHBY 的股票。波士顿共同资产管理公司在第二季度增持了罗氏的股份，增幅为 11.1%。波士顿共同资产管理公司现在拥有 361,833 股公司股票，价值为 14,682,000 美元，此前在上个季度增持了 36,101 股。OLD National Bancorp IN 在第二季度将其在罗氏的持仓提高了 2.9%。OLD National Bancorp IN 现在拥有 261,317 股公司股票，价值为 10,604,000 美元，此前在此期间购买了 7,326 股。Rhumbline Advisers 在第二季度增持了罗氏的股份，增幅为 1.1%。Rhumbline Advisers 现在拥有 108,480 股公司股票，价值为 4,422,000 美元，此前在上个季度增持了 1,228 股。Yousif Capital Management LLC 在第二季度将其在罗氏的持仓增加了 7.8%。Yousif Capital Management LLC 现在拥有 88,547 股公司股票，价值为 3,593,000 美元，此前在此期间增持了 6,395 股。最后，S&amp;CO Inc.在第一季度将其在罗氏的股份提高了 4.1%。S&amp;CO Inc.现在拥有 51,199 股公司股票，价值为 2,101,000 美元，此前在上个季度购买了 2,014 股。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts recently commented on the company. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a report on Wednesday, October 29th. HSBC upgraded Roche from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $50.00 price objective on the stock in a research report on Thursday, October 2nd. Deutsche Bank Aktiengesellschaft raised shares of Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 11th. Hsbc Global Res raised shares of Roche from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Thursday, October 2nd. Finally, Jefferies Financial Group lowered shares of Roche from a &#34;hold&#34; rating to a &#34;moderate sell&#34; rating in a research report on Monday, October 27th. Three analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of &#34;Buy&#34; and an average price target of $50.00.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。摩根士丹利在 10 月 29 日的报告中重申了对罗氏股票的 “减持” 评级。汇丰银行在 10 月 2 日的研究报告中将罗氏的评级从 “持有” 上调至 “买入”，并设定了 50.00 美元的目标价。德意志银行在 11 月 11 日的报告中将罗氏的评级从 “卖出” 上调至 “持有”。汇丰全球研究在 10 月 2 日的报告中将罗氏的评级从 “持有” 上调至 “强力买入”。最后，杰富瑞金融集团在 10 月 27 日的研究报告中将罗氏的评级从 “持有” 下调至 “适度卖出”。三位分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “买入”，平均目标价为 50.00 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on RHHBY</strong></p>
<div class="lb-trans"><p><strong>获取我们对 RHHBY 的最新分析</strong></p>
</div><h2>Roche Stock Up 2.3%</h2>
<div class="lb-trans"><h2>罗氏股票上涨 2.3%</h2>
</div><p>Shares of RHHBY stock opened at $49.01 on Friday. Roche Holding AG has a 1-year low of $34.10 and a 1-year high of $49.20. The stock has a 50 day simple moving average of $43.38 and a 200-day simple moving average of $41.31.</p>
<div class="lb-trans"><p>RHHBY 股票在周五开盘时为 49.01 美元。罗氏控股公司的一年低点为 34.10 美元，一年高点为 49.20 美元。该股票的 50 日简单移动平均线为 43.38 美元，200 日简单移动平均线为 41.31 美元。</p>
</div><h2>About Roche</h2>
<div class="lb-trans"><h2>关于罗氏</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><ul>
<li>NVIDIA Invested in These 2 AI Stocks, Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>NVIDIA 投资了这两只 AI 股票，你应该投资吗？</li>
</ul>
</div><p>Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.</p>
<div class="lb-trans"><p>罗氏控股公司在欧洲、北美、拉丁美洲、亚洲、非洲、澳大利亚和大洋洲从事制药和诊断业务。该公司在贫血、血液和实体肿瘤、皮肤病、血友病、炎症和自身免疫、神经系统疾病、眼科、呼吸系统疾病和移植等治疗领域提供药品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Roche</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>MP Materials Stock Soared After Earnings—Here’s the Real Reason</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Why Palantir Slide May Be a Setup for a Long-Term Opportunity</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>专家股票交易心理学技巧</li>
<li>MP Materials 股票在财报后飙升——真正原因是什么</li>
<li>股票情绪分析：如何运作</li>
<li>为什么 Palantir 的下滑可能是长期机会的铺垫</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>收入投资者注意：这只 REIT 正在打折</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RHHBY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 RHHBY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=OTCMKTS&amp;Symbol=RHHBY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Roche Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在罗氏吗？</h2>
</div><p>Before you consider Roche, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑罗氏之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而罗氏并不在名单上。</p>
</div><p>While Roche currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然罗氏目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

企业金融服务公司购买了 5,108 股罗氏 (ADR) $RHHBY